A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation

Defined as the time (in days) between the date of first Venetoclax intake to date of death.

Defined as the percentage of participants with either complete response (CR) or complete response with incomplete hematological recovery (CRi) according to physician's assessment.

Defined as the percentage of participants with either CR or CRi according to physician's assessment during Venetoclax treatment.

Defined as the percentage of participants with CR according to physician's assessment during Venetoclax treatment.

Defined as the time (in weeks) between the date of first Venetoclax intake to first response, among CR, CRi, and morphologic leukemia free state (MLSF).

Defined as the time (in weeks) between the date of first Venetoclax intake and the date of hte assessment having documented the best response among CR, CRi, and MLSF.

Defined as the time (in weeks) between the date of the first assessment documenting the response to Venetoclax (either CR, CRi, or MLSF) and the date of the first assessment having documented the progression.

Defined as the time (in weeks) between the date of first Venetoclax intake and the date of the first assessment having documented disease progression (primary refractory disease, or relapse from CR, CRi, or death from any cause).

Defined as the time between the date of CR and the date of the first assessment having documented disease progression or death from any cause.

Defined as the time (in weeks) between the date of first Venetoclax intake and the absence of any red blood cell (RBC) or platelet transfusion during any consecutive 8 weeks during the treatment period.

Defined as the percentage of participants treated with Venetoclax in combination with hypomethylating agents (HMAs).

Defined as the percentage of participants treated with Venetoclax in combination with low dose cytarabine (LDAC).

Defined as the percentage of participants treated with Venetoclax in combination with other therapeutic agents

Percentage of participants with dose modifications.

Percentage of participants with dose interruptions

Percentage of participants taking concimtant CYP3A medications while treated with Venetoclax.

An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity after the first dose of study drug.